


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission 0

Application Number	10/723,681
Filing Date	November 25, 2003
First Named Inventor	Roth, Richard
Art Unit	1632
Examiner Name	To Be Assigned
Attorney Docket Number	SEQ-4069-UT

ENCLOSURES (Check all that apply)

- ☐ Fee Transmittal Form
- ☐ Fee Attached
- ☐ Amendment/Reply
- ☐ After Final
- ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement

- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation
- ☐ Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) _____
- ☐ Landscape Table on CD

- ☐ After Allowance Communication to TC
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☐ Other Enclosure(s) (please identify below):

- ☐ Certified Copy of Priority Document(s)
- ☐ Reply to Missing Parts/Incomplete Application
- ☐ Reply to Missing Parts under 37 CFR 1.52 or 1.53

Remarks

SB08 - 1 page
cover letter - 2 pages
return post card - 1 page
transmittal form in duplicate - 2pages

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	BioTechnology Law Group		
Signature			
Printed name	Bruce Grant		
Date	SEPTEMBER 19, 2005	Reg. No.	47,608


CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Bruce Grant	Date	SEPT. 19, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	ROTH et al	Examiner:	To Be Assigned
Serial No.:	10/723,681	Group Art Unit:	1632
Filed:	November 25, 2003	Docket:	SEQ-4069-UT
Title:	METHODS FOR IDENTIFYING RISK OF BREAST CANCER AND TREATMENTS THEREOF		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam,

In compliance with the duty under 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the Examiner's attention for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form SB08A be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the SB08A form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication. Applicants also bring to the Examiner's attention the existence of the following co-pending related applications: (1) application no. 10/723,142 (Attorney Docket: SEQ-4065-UT), November 25, 2003, (2) application no. 10/723,670 (Attorney Docket: SEQ-4067-UT), filed November 25, 2003, (3) application no. 10/723,518 (Attorney Docket: SEQ-4068-UT), filed November 25, 2003, (4) application no. 10/857,780 (Attorney Docket: SEQ-4069-CP), filed May 27, 2004, (5) application no. 10/722,939 (Attorney Docket: SEQ-4071-UT), filed November 25, 2003, and (6) application no. 10/723,683 (Attorney Docket: SEQ-4072-UT), filed November 25, 2003.

INFORMATION DISCLOSURE STATEMENT

Serial No.: 10/723,681

Filing Date: November 25, 2003

Title: METHODS FOR IDENTIFYING RISK OF BREAST CANCER AND TREATMENTS THEREOF

Page 2

Dkt: SEQ-4069-UT

The listed documents are being submitted in compliance with 37 CFR § 1.97(b), before the mailing date of the first office action on the merits. Accordingly, it is respectfully submitted no fees are due.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

Date SEPTEMBER 19, 2005

BioTechnology Law Group

658 Marsolan Ave.


Solana Beach, CA 92075

Telephone: (858) 623-9470

Fax: (858) 623-9476

Email: bruce@biotechnologylawgroup.com

By



Bruce Grant

Reg. No. 47,608

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

SEP 23 2005



Sheet 1 of 1

Complete if Known

Application Number 10/723,681

Filing Date November 25, 2003

First Named Inventor Roth, Richard

Group Art Unit 1632

Examiner Name To Be Assigned

Attorney Docket No: SEQ-4069-UT

US PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1.	US 5,547,835	Aug-96	Koster	
	A2.	US 5,605,798	Feb-97	Koster	
	A3.	US 5,691,141	Nov-97	Koster	
	A4.	US 5,849,542	Dec-98	Reeve et al.	
	A5.	US 5,869,242	Feb-99	Kamb	
	A6.	US 5,928,906	Jul-99	Koster et al.	
	A7.	US 6,043,031	Mar-00	Koster et al.	
	A8.	US 6,194,144	Feb-01	Koster	
	A9.	US 6,258,538	Jul-01	Koster et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
	A10.					

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A11.	Elbashir et al., Methods 26(2):199-213 (2002)	
	A12.	Forbes, Seminars in Oncology, 24(1)Suppl. 1: S1-20 - S1-35 (1997)	
	A13.	Ford et al., British J. Cancer, 72:805-812 (1995)	
	A14.	Miki et al., Science, 266:66-71 (1994)	
	A15.	NCBI database, NCBI, NLM, NIH (Bethesda MD, USA) Accession # AI 199660 NCBI Assay ID ss3752266 Dec 12, 1998	
	A16.	NCBI database, NCBI, NLM, NIH (Bethesda MD, USA) Accession # SNP rs11549918 NCBI Assay ID ss16249946 November 2003	
	A17.	Wooster et al., Science, 265:2088-2090 (1994)	

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached